Atrium Therapeutics, Inc. (RNA) has 20 既知のインサイダーおよび機関投資家保有者の記録. 最大保有者は RTW INVESTMENTS, LP 4,795,000 株保有. その他の主要保有者には Boyce Sarah および Edwards Martin.
過去12ヶ月間にインサイダーは 12 件の取引を実施 RNA 株式 — 8 件の買い (評価額 $674.69K) および 2 件の売り (評価額 $685.24K). インサイダーの買いが売りを上回っており、会社の見通しに対する自信の表れかもしれません.
RNA インサイダー保有状況
最大保有者
RTW INVESTMENTS, LP
4,795,000 株
インサイダー上位保有者
| # |
氏名 |
役職 |
保有株数 |
最終申告日 |
相対規模 |
| 1 |
Rtw Investments, Lp |
10 Percent Owner |
4,795,000 |
2021-08-06 |
|
| 2 |
Boyce Sarah |
President and CEO |
305,871 |
2025-03-21 |
|
| 3 |
Edwards Martin |
Director |
136,776 |
2021-01-04 |
|
| 4 |
Mccarthy Teresa |
Chief Human Resources Officer |
97,130 |
2025-03-21 |
|
| 5 |
Maclean Michael F |
Chief Financial Officer |
96,720 |
2025-03-21 |
|
| 6 |
Baroldi Joseph |
Chief Operating Officer |
87,000 |
2021-02-04 |
|
| 7 |
Kim Jae B. |
Chief Medical Officer |
82,000 |
2021-02-04 |
|
| 8 |
Flanagan W. Michael |
Chief Scientific Officer |
80,195 |
2025-06-12 |
|
| 9 |
Hughes Steven George |
Chief Medical Officer |
72,850 |
2025-03-21 |
|
| 10 |
Gallagher Kathleen P. |
Chief Program Officer |
50,392 |
2025-06-18 |
|
| 11 |
Mosbrooker Eric |
Chief Commercial Officer |
50,000 |
2025-01-08 |
|
| 12 |
Moriarty John B |
Chief Legal Officer |
50,000 |
2025-01-08 |
|
| 13 |
Calderaro Charles Iii |
Chief Technical Officer |
40,000 |
2025-01-08 |
|
| 14 |
Wong Roderick |
10 Percent Owner |
15,000 |
2021-06-17 |
|
| 15 |
Levin Arthur A |
Director |
10,034 |
2025-06-12 |
|
| 16 |
Wilson Troy Edward |
Director |
10,034 |
2025-06-12 |
|
| 17 |
Skerjanec Simona |
Director |
6,692 |
2025-06-12 |
|
| 18 |
Henig Noreen |
Director |
6,692 |
2025-06-12 |
|
| 19 |
Boess Carsten |
Director |
6,692 |
2025-06-12 |
|
| 20 |
Kaye Edward M. Md |
Director |
6,692 |
2025-06-12 |
|
最近の取引 (過去12ヶ月)
| 日付 |
氏名 |
役職 |
種類 |
株数 |
株価 |
価値 |
| 2025-06-17 |
Gallagher Kathleen P. |
Chief Program Officer |
情報に基づく売り |
911 |
$30.24 |
$27.55K |
| 2025-06-10 |
Skerjanec Simona |
Director |
RSU 付与（制限付株式） |
6,692 |
- |
- |
| 2025-06-11 |
Flanagan W. Michael |
Chief Scientific Officer |
情報に基づく売り |
20,000 |
$32.88 |
$657.69K |
| 2025-06-10 |
Kim Jean Jinsun |
Director |
RSU 付与（制限付株式） |
6,692 |
- |
- |
| 2025-06-10 |
Thompson Tamar |
Director |
RSU 付与（制限付株式） |
6,692 |
- |
- |
| 2025-06-10 |
Henig Noreen |
Director |
RSU 付与（制限付株式） |
6,692 |
- |
- |
| 2025-06-10 |
Wilson Troy Edward |
Director |
RSU 付与（制限付株式） |
10,034 |
$33.62 |
$337.34K |
| 2025-06-10 |
Kaye Edward M. Md |
Director |
RSU 付与（制限付株式） |
6,692 |
- |
- |
| 2025-06-10 |
Boess Carsten |
Director |
RSU 付与（制限付株式） |
6,692 |
- |
- |
| 2025-06-10 |
Levin Arthur A |
Director |
RSU 付与（制限付株式） |
10,034 |
$33.62 |
$337.34K |
| 2025-06-02 |
Gallagher Kathleen P. |
Chief Program Officer |
オプション行使（売却） |
5,875 |
$16.65 |
$97.82K |
| 2025-05-01 |
Gallagher Kathleen P. |
Chief Program Officer |
オプション行使（売却） |
5,875 |
$16.65 |
$97.82K |
